Amphastar Pharmaceuticals, Inc. (AMPH) is a renowned American-based biopharmaceutical company focusing on the development, manufacturing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company was incorporated in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals provides its products to hospitals, care organizations, international healthcare facilities, and clinics that need generic and specialized pharmaceuticals for their patients. The company's broad portfolio includes products used in areas such as critical care, cardiac care, trauma care, and respiratory health. Some of the primary active pharmaceutical ingredients in its products include heparin, lidocaine, lorazepam, and morphine.
The company's extensive range of products includes Enoxaparin Sodium Injection, a generic anticoagulant; Amphadase, hyaluronidase injection; and Cortrosyn, a diagnostic drug. The company is known for its devotion to research and development, with many new products usually in various stages of development. Besides, Amphastar Pharmaceuticals holds several patent protections for its technologically innovative and clinically useful pharmaceutical products.
Amphastar Pharmaceuticals has grown substantially over the years. It operates manufacturing facilities in California, Indiana, and even internationally in France, China, and also owns a research and development facility in Canada. Furthermore, the company made headlines when it acquired International Medication Systems, Limited in 2005, and Merck’s active pharmaceutical ingredient manufacturing facility in France in 2009. These acquisitions have bolstered the company's manufacturing capabilities and expanded its market access.
Moreover, the company remains financially robust, generating substantial revenues from the sale of its pharmaceuticals. It has a healthy stock market listing with its shares traded on the NASDAQ.
However, the company isn't just about profits; it is dedicated to improving patient care by delivering high-quality, affordable medications that address unmet medical needs. As well, Amphastar Pharmaceuticals places great importance on core values such as integrity, innovation, and commitment, thus enhancing its corporate reputation in the healthcare industry.
In summary, Amphastar Pharmaceuticals, Inc. stands out as a formidable player in the pharmaceutical industry, continually striving to make important contributions to global healthcare. The company's commitment to research, along with its dedication to quality and affordability, has not only led it to its current success but also set a firm foundation for future achievements.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters sold 4,139 shares of the company's stock for a total of $103,475 under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Peters still directly owns 168,707 shares valued at approximately $4.2 million. The company recently reported strong quarterly earnings, significantly beating analyst estimates, although the consensus analyst rating remains "Reduce" with an average price target below the current trading price.
Amphastar Pharmaceuticals EVP Rong Zhou sold 10,000 shares of the company's stock for $239,400, reducing her direct holdings by 5.58% to 169,203 shares. Despite the sale, Amphastar reported strong quarterly earnings, beating EPS and revenue estimates. Analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $22.50.
Squarepoint Ops LLC significantly increased its stake in Amphastar Pharmaceuticals, Inc. by 178% in the second quarter, now holding 78,795 shares valued at $1.59 million. Despite this increase in institutional investment, analysts maintain a cautious "Reduce" rating for AMPH with a consensus price target of $22.50. The company recently surpassed quarterly earnings and revenue expectations, but corporate insiders have sold shares totaling $421,047 during the last quarter.
Legal & General Group Plc has made a new investment of $1.58 million in Amphastar Pharmaceuticals (NASDAQ:AMPH), acquiring 78,281 shares, which represents a 0.18% stake. This investment comes as Amphastar Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. Despite positive earnings, analyst sentiment remains cautious with a consensus "Reduce" rating and insider selling activity observed over the past three months.
Bank of New York Mellon Corp recently acquired a new stake of 232,343 shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), valued at approximately $4.7 million. This investment gives Bank of New York Mellon Corp a 0.53% ownership stake in the company. Despite this institutional interest and strong Q2 earnings that beat analyst estimates, analyst sentiment remains cautious with an average "Reduce" rating for Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received a "Reduce" consensus rating from analysts, with an average 12-month price target of $22.50, which is below its current share price of $23.18. Despite this, the company reported strong quarterly results, exceeding earnings and revenue expectations. Recent insider selling and increased institutional investor positions indicate mixed sentiment around the stock.